Clay B. Siegall

Clay Siegall has held various roles throughout their work experience. Clay has served as a Director on the Board of Directors for Ultragenyx Pharmaceutical since 2014, Mirna Therapeutics, Inc. since 2013, and Alder Biopharmaceuticals Inc. since 2006. Prior to these positions, they served as the President & CEO of Seattle Genetics starting in 1998.

Clay Siegall holds a Bachelor of Science (B.S.) degree in Zoology from the University of Maryland. Clay also earned a Doctor of Philosophy (Ph.D.) degree in Genetics from The George Washington University.